Finanzen von SCTX (SCTX)SCTXSCTX

Evaluating the bottom line, Scribe Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -556.52%, while the net margin is -776.85%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively SCTX converts its operational activities into shareholder value.

In the context of the broader market, SCTX competes directly with industry leaders such as VALN and CABA. With a market capitalization of $543.14M, it holds a significant position in the sector. When comparing efficiency, SCTX's gross margin of 100.00% stands against VALN's 9.60% and CABA's N/A. Such benchmarking helps identify whether Scribe Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The stock has a negative P/E ratio of -26.19 and a forward P/E of 0, indicating potential challenges in profitability. However, it has shown a significant year-to-date change of +89.60%, reflecting strong long-term growth.